Wednesday, June 24, 2026

#France, #Ebola: First case identified in a humanitarian #doctor returning from a mission in the #DRC (Min. Health, June 24 '26)

 


    France has specialized capabilities for managing highly transmissible infectious diseases. Patients are treated in a designated healthcare facility, following strict biosafety protocols (negative pressure room, dedicated equipment and protocols). Health authorities are fully mobilized and the situation is being continuously monitored.


    All precautionary measures, including the patient's isolation, were taken upon his arrival in the country, with transfer to the hospital under secure conditions to prevent any risk of contamination. 

    A thorough epidemiological investigation is underway to identify individuals who may have been in contact with the patient. 

    These individuals will be contacted without delay by the regional health agency, will undergo 21 days of home isolation, and will be closely monitored during this period. 

    Following the Public Health Emergency of International Concern (PHEIC) declared by the World Health Organization (WHO) on May 17 in response to the active circulation of the Ebola virus in Ituri Province, DRC, the European Centre for Disease Prevention and Control (ECDC) has assessed the risk of infection as low for European residents and travelers to areas of active transmission, and very low for the general European population.

    A dedicated monitoring system is in place for the return of French aid workers to the national territory.


What is the Ebola virus?

    Ebola virus disease is a serious and often fatal illness. The virus is transmitted to humans from wild animals and then from person to person through direct contact with:

        ° Bodily fluids (blood, saliva, urine, semen, breast milk, sweat, feces and vomit from infected persons, whether alive or not);

        ° The bodies of people who died from Ebola virus disease;

        ° Objects that have been contaminated by the bodily fluids of infected patients (e.g., needles);

        ° Bushmeat from wild animals.

    The disease is characterized by high fevers and often fatal hemorrhages. 

    The incubation period, that is, the time between contact with the virus and the appearance of the first symptoms, varies from 2 to 21 days

    As long as they do not show symptoms, infected individuals are not contagious. 

    Currently, there is no specific treatment for Ebola {Bundibugyo virus} disease; treatment focuses on managing the symptoms, particularly through rehydration.


What are the health recommendations?

    Given the absence of the virus circulating on French territory, the precautionary health recommendations apply mainly to the French territories bordering the Indian Ocean, and to travelers going to or returning to the DRC in the provinces of Ituri, North Kivu and South Kivu and Uganda.

    {1} For French nationals currently in the country, it is recommended to avoid areas experiencing outbreaks of the epidemic and, if this is impossible, to:

        ° Respect basic hygiene rules, including regular hand washing;

        ° Avoid close contact with people who have a fever. The virus is transmitted through direct contact with blood or bodily fluids;

        ° Avoid all contact with wild animals, alive or dead;

        ° Do not consume or handle bushmeat.

    {2} For travelers going to areas where the virus is circulating, it is recommended that those who can postpone their trip, especially the most vulnerable (elderly people, people with disabilities, pregnant women, or those with comorbidities). If the trip must proceed, it is recommended to follow the aforementioned health guidelines and to:

        ° Regularly consult the information from the embassy or the "Travel Advice" section of the Ministry for Europe and Foreign Affairs;

        ° Register for free on the Ariane Thread , in order to receive in real time all information and alerts from the French authorities;

    {3} For travelers returning to France from an area with active virus transmission, the following is required:

        ° Monitor your temperature every day for 21 days;

        ° If you develop a fever of 38°C or higher, and up to 21 days after returning to France, contact 15 immediately and await instructions. Do not go to your doctor or the hospital emergency room.

(...)

Source: 


Link: https://sante.gouv.fr/actualites-presse/presse/communiques-de-presse/article/ebola-identification-d-un-1er-cas-chez-un-medecin-humanitaire-de-retour-de

____

#WHO DG's opening #remarks at the media #briefing – 24 June 2026 {#Ebola in #DRC} (Edited): #France reported a NGO #HCW positive for the virus

 


    Good afternoon to those in the room, and good morning, good afternoon and good evening to those online, wherever you are in the world.

    We begin with the Ebola outbreak in the Democratic Republic of the Congo.

    It’s encouraging to see that since the outbreak was first reported five weeks ago, the response has scaled up significantly, under the leadership of the government.

    In the past five weeks, the number of treatment beds has increased from less than 10 to over 500 in 19 health centres.

    With support from WHO and the Africa CDC, laboratory capacity has increased from 30 tests a day at the central laboratory in Kinshasa to over 2000 tests a day in nine labs across three provinces.

    More communities are becoming aware of the risks of Ebola, and asking for the tools and support to protect themselves.

    And more than 100 people have now recovered. With early detection and supportive care, many can survive this disease.

    But we could save many more lives with therapeutics.

    Preparations are now complete for a trial of two therapeutics that is expected to start in DRC next week.

    The trial will evaluate whether two antivirals, MBP134 and remdesivir, can help to reduce mortality in patients with Bundibugyo virus disease, alone or in combination.

    We thank the United States and Gilead Sciences for donating doses for the trial. Together with our partners we will announce more information next week.

    WHO and our partners are working closely with the communities to inform and involve them in the trial.

    We are also working to ensure the communities have access to the therapeutics should they prove safe and efficacious.

    The trial will be conducted by a consortium of partners including DRC’s National Institute for Biomedical Research, ALIMA, Oxford University and WHO.

    Despite the good progress we have made, we still face major challenges, and the outbreak is continuing to outpace the response.

    There are now 1094 confirmed cases, with 277 deaths.

    The outbreak is continuing to move fast.

    Political advocacy and action are essential to create the conditions for increased humanitarian access and a scaled-up response, because the outbreak is happening in a complex situation.

    In neighbouring Uganda, a new case was reported last Sunday, the first in two weeks.

    This brings the total in Uganda to 20 confirmed cases, with two confirmed deaths.

    All cases in Uganda are linked to the outbreak in DRC.

    Today, France reported that a health worker with the NGO ALIMA, who returned to the country after caring for an Ebola patient in DRC, tested positive for the virus, and is now being monitored and receiving care.

    This case is a reminder of the risks faced by frontline responders.

    Almost 80 health workers have been infected, highlighting the risks they face and the importance of strengthening infection prevention and control.

    WHO advises countries to support the safe deployment of personnel responding to this outbreak.

    This includes ensuring that organizations deploying staff provide clear information on risks, how to reduce and manage the risk of exposure, and that countries are prepared to facilitate evacuation if needed.

    Still, the risk to the rest of the world remains low.

    Under the government’s leadership, the coordinated response to the outbreak is starting to take hold.

    But continued scale up is needed.

    Contact tracing is still not at the level needed;

    Capacity at treatment and isolation centres is insufficient;

    Safe and dignified burials remain a major challenge;

    The health system is under pressure;

    Border closures continue to hinder the response;

    Multiple security incidents have been reported;

    The affected area is in the grip of a decades-long humanitarian crisis;

    And financial support is still insufficient.

    Earlier this month, WHO and the Africa CDC announced a joint Continental Preparedness and Response Plan that reflects the funding needs of partners, with an ask of 518 million U.S. dollars.

    Next week, the first financial reporting on pledges and commitments to the plan are expected to be available, providing a clear understanding of gaps and needs. 


===

    Now to the outbreak of hantavirus.

    The total number of cases from the hantavirus outbreak remains 13, including three deaths.

    In all, more than 650 contacts have been identified and followed up by local health authorities in 33 countries and territories.

    All but 54 contacts have completed their period of quarantine, and the remaining contacts are scheduled to complete their quarantine period by the 2nd of July.

    If no further cases are reported by then, WHO will consider the outbreak to be over.

    However, WHO will continue working to advance our understanding of this outbreak, and hantavirus more generally.

    Working with governments and partners, we are continuing investigations into how the outbreak started and spread among those on board.

    We are also working with partners who have collected environmental samples onboard the ship.

    In addition, we are coordinating a study among people exposed to the virus involving 21 countries, to better understand how the disease develops.

    We are also working on having a sample of the virus shared with the WHO BioHub in Switzerland.

    This will be important for developing diagnostics, therapeutics and vaccines for future outbreaks.

    I thank all countries that have contributed in different ways to the response to this outbreak, with special thanks to the leadership and solidarity shown by Spain, especially to Prime Minister Pedro Sánchez.

    I also thank the Captain of the MV Hondius, Captain Jan Dobrogowski, his crew and all passengers for their cooperation in what has been a very difficult situation.

(..)

Source: 


Link: https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-media-briefing---24-june-2026

____

#Bundibugyo #Ebola in #DRC and #Uganda: #community-centred #response must be operational, not rhetorical

 


{Excerpt}

On May 15, 2026, the Ministry of Public Health, Hygiene and Social Welfare of DR Congo declared the country's 17th recorded Ebola disease outbreak after the Institut National de Recherche Biomédicale confirmed Bundibugyo virus (species Orthoebolavirus bundibugyoense) as the aetiological agent.1 That this outbreak was caused by Bundibugyo virus is not a taxonomic footnote. It changes the diagnostic, countermeasure, and risk-communication context of the response.2

(...)

Source: The Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/home


____

Identification of HLA-A33-restricted #CD8+ T cell epitopes from avian #influenza #H5N1

 


Abstract

The rapid evolution of avian influenza A/H5N1, including the recent U.S. clade 2.3.4.4b outbreak, highlights its pandemic potential and the urgent need for durable, broadly protective vaccines. Given the capacity of CD8+ T cells to mediate cross-strain immunity, we investigated whether geographically distinct HLA-A33 allotypes, HLA-A*33:01 in East/Southeast Asia and HLA-A*33:03 in South Asia, differentially shape the influenza immunopeptidome and influence antiviral immunity. Antigen-presenting cells overexpressing HLA-A*33:01 or HLA-A*33:03 were transfected with single A/H5N1 antigens or infected with A/X-31 (H3N2) as a control comparison representing current seasonal influenza virus. We identified novel ligands restricted to HLA-A*33:01 (57 from A/H5N1; 55 from A/X-31) and HLA-A*33:03 (29 from A/H5N1; 45 from A/X-31). Although fewer peptides were recovered for HLA-A*33:03, a larger proportion of A/X-31-derived peptides were predicted as high-affinity binders (74%) compared with HLA-A*33:01 (61%), indicating qualitative differences in antigen presentation. To determine immunogenicity, peripheral blood lymphocytes from HLA-A*33:03-positive, A/H5N1-naïve donors were stimulated with four conserved peptides: PB2GTF, PB2KTY, NPSVQ and PB1MTK. All elicited robust CD8+ T cell activation despite the absence of prior A/H5N1 exposure, demonstrating cross-recognition by memory T cells primed against seasonal influenza. These findings define HLA-A33-restricted influenza epitopes and reveal allotype-specific presentation features that shape CD8+ T cell immunity. Conserved, immunogenic peptides identified here represent promising candidates for rational design of broadly cross-reactive vaccines to protect HLA-A33-expressing populations against severe A/H5N1 disease. Data are available via ProteomeXchange with identifier PXD078870.


Competing Interest Statement

AWP is a scientific advisor for Bioinformatics Solutions Inc (Canada), a shareholder and scientific advisor for Evaxion Biotech (Denmark), and a co-founder of Resseptor Therapeutics (Australia). These organisations had no role in the design of the study in the collection, analyses, or interpretation of data in the writing of the manuscript or in the decision to publish the results. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.


Funder Information Declared

NHMRC, 1122099, 2016596

Source: BioRxIV, https://www.biorxiv.org/

Link: https://www.biorxiv.org/content/10.64898/2026.06.21.733083v1

____

Tuesday, June 23, 2026

#Antibodies against #influenza #H1N1pdm2009 and B/Victoria strains but not #H3N2 are increased in recent onset type 1 #narcolepsy versus matched controls

 


Abstract

Study Objectives

Onsets of Narcolepsy type-1 (NT1) increased following A/H1N1 vaccination with PandemrixTM in Europe and with A/H1N1pdm2009 infections in China and other countries. To test if other strains could trigger narcolepsy, we measured strain-specific antibodies in patients with recent onset NT1 compared to controls. 

Methods

Antibodies against hemagglutinin (HA) and neuraminidase (NA) were tested in 62 patients with very recent onset (onset and blood collection following a single flu season, mean +/- SEM: 0.44 +/- 0.06 years since onset) and 100 controls matched by age, sex, season and year of collection (2000-2025). Results were next extended to 181 recent onset patients (mean +/- SEM: 1.00 +/- 0.05 years) versus 260 controls, matched by sex, season and year, but having a slightly higher mean age. HA inhibition (HAI) and NA inhibition (NAI) assays were conducted using flu strains known to circulate during the corresponding flu seasons. HAI results are shown as % positive (titers >= 40) and NAI results as geometric mean titers. Odds ratio (OR) and coefficient were used to compare antibody titers in NT1 versus controls. The contribution of each assay to prediction was finally quantified in the larger sample set using Shapley decomposition. 

Results

NT1 patients had increased anti-HA and anti-NA antibodies against A/H1N1pdm2009 (anti-HA OR = 3.86, anti-NA coefficient = 0.35) and B/Victoria (anti-HA OR =1.90, anti-NA coefficient = 0.22), but not A/H1N1pre2009, A/H3N2, or B/Yamagata, independent of HLA-DQB1*06:02 status, age, sex, and flu season. Correlations between anti-HA and anti-NA antibodies titers were weak to moderate but significant (r2=-0.10 to 0.34). Multivariable model outperformed age-only baseline (McFadden R2 = 0.19 vs. 0.03; AUC = 0.79 vs. 0.64; likelihood-ratio test X2 = 51, p<0.001), with anti-HA against A/H1N1pdm2009 (coefficient = 0.78, p < 0.001) and anti-NA against B/Victoria (coefficient = 0.69, p < 0.001) emerging as the strongest independent predictors. 

Conclusions

A/H1N1pdm2009 and B/Victoria, but not other strains can trigger the autoimmune process leading to orexin cell loss in narcolepsy.


Competing Interest Statement

The authors have declared no competing interest.

Source: 


Link: https://www.medrxiv.org/content/10.64898/2026.06.13.26355596v1

____

Deep #mutational #scanning of recent #SARS-CoV-2 #variants highlights changing amino acid preferences within epistatic hotspot residues

 


Abstract

Deep mutational scans across receptor-binding domains (RBDs) of diverging SARS-CoV-2 variants reveal ongoing changes to the effects of mutations, a phenomenon known as epistasis. Careful accounting for these altered mutational effects is important in viral surveillance and forecasting, and more broadly, for understanding the impacts of epistasis on real-world viral evolutionary trajectories. Using a yeast-display RBD deep mutational scanning (DMS) platform, we measure the impacts of virtually all single amino acid mutations and single-residue deletions in the Omicron KP.3.1.1 and LP.8.1 RBDs on folded RBD expression and binding affinity for the human ACE2 receptor. Our comprehensive maps reveal patterns of evolutionary accessibility and constraint at single-residue resolution and, when compared to prior datasets, highlight sites whose amino acid preferences continue to change across viral variants. Notably, sites 455, 456, and 493 – which have exhibited repeated substitutions and epistatic dependencies across Omicron subvariants going back to BA.1 – again demonstrate altered patterns of mutational accessibility and constraint. Therefore, it appears that these hotspots of repeated RBD evolution have not yet converged on fixed amino acid solutions but instead remain sites of ongoing epistatic reconfiguration. We compare our measurements of direct RBD:ACE2 affinity with recently published measurements of mutation impacts on ACE2 binding in the full quaternary spike context, which also integrates the effects of spike conformational dynamics; our analysis uncovers mutations like H505W that could favor adoption of the down/closed RBD conformation as a viral strategy for future antigenic evolution.

Source: 


Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014074

____

Neurosurgical #Biopsy and #Resection for #Diagnosis and #Treatment of #Balamuthia mandrillaris Amebic #Encephalitis, #USA

 


Abstract

We report a systematic case review of antemortem neurosurgical resections and biopsies and outcomes including new lesions after procedure and survival in Balamuthia mandrillaris granulomatous amebic encephalitis. The investigation was prompted by a 5-year-old patient in the southwestern United States who was treated with nitroxoline, the 2021 Centers for Disease Control and Prevention regimen, and underwent 2 resections; initial resection site recurrence and a new lesion after resection prompted the question whether complete resection versus biopsy is associated with better outcomes. We conducted a literature review and found no substantial difference between neurosurgical resection versus biopsy-only groups. Limitations include case review, number of cases, and incomplete data available. Additional analyses comparing neurosurgical outcomes with outcomes of those diagnosed via blood or cerebrospinal fluid and metagenomic next-generation sequencing might provide more definitive answers. This case and systematic review provide evidence that treatment with nitroxoline and neurosurgical resection could contribute to survival in Balamuthia encephalitis case-patients.

Source: 


Link: https://wwwnc.cdc.gov/eid/article/32/7/26-0725_article

____

Avian #Influenza #Report - Reporting period: June 14 - 20 '26 (Wk 25) (HK CHP, June 23 '26): One New #Human Case of #Infection with #H9N2 virus in #China

 


{Excerpt}

(...)

Avian influenza A(H9N2)

    ° Guangxi Zhuang Autonomous Region

        * A two-year-old girl with onset on May 31, 2026. 

(...)

Source: 


Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk25.pdf

____

Institutionalising public #health #emergency #preparedness and responses in #Africa: lessons learned during the 2022-2025 #outbreaks with crossborder spread potential

 


Summary

Lessons and best practices from outbreaks during 2022–25 in Africa were not comprehensively documented or shared to inform future outbreak responses. We conducted a narrative review of published articles and outbreak response reports of mpox, cholera, Ebola virus disease, and Marburg virus disease and captured experts' perspectives and lessons. We analysed and presented the data in themes. Evidence indicates that effective responses are built on routine investments maintained between outbreaks, particularly in decentralised laboratories, digital surveillance systems, community structures, and clinical trial readiness. The institutionalisation of response mechanisms through national public health institutes, incident management systems, and emergency operations centres reflects a maturing continental preparedness architecture, reinforced by rapid regional solidarity, south–south cooperation, and timely partner support. National political leadership was crucial in mobilising resources and ensuring public compliance, whereas innovations such as expanded genomic surveillance, timely deployment of investigational countermeasures, mobility-aware outbreak control, and improved early-warning systems strengthened responses to outbreaks. The successful control of these recent outbreaks highlights the importance of strengthening preparedness, institutionalising response systems, and fostering coordinated, Africa-led health security frameworks to support resilient and sustainable outbreak response.

Source: 


Link: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00160-9/fulltext

____

Monday, June 22, 2026

Isotopic #evidence for a cold and distant #origin of #3IATLAS {Comet}

 


Abstract

Interstellar objects provide the only directly observable samples of icy planetesimals formed around other stars, and can therefore provide insight into the diversity of physical and chemical conditions occurring during exoplanet formation1−3. Here we report isotopic measurements of the interstellar comet 3I/ATLAS, which reveal an elemental composition unlike any Solar System body. The water in 3I/ATLAS is enriched in deuterium, at a level of D/H = (0.98 ± 0.06)%, which is more than an order of magnitude higher than in known comets, while its range of 12C/13C ratios (141–191 for CO2 and 123–172 for CO) exceeds typical values found in the Solar System, as well as nearby interstellar clouds and protoplanetary disks. Such extreme isotopic signatures indicate formation at temperatures  ≲ 30 K in a relatively metal-poor environment. When interpreted with respect to models for Galactic chemical evolution, the carbon isotopic composition implies that 3I/ATLAS may have accreted as long ago as 12 billion years, following a period of intense, early star formation. 3I/ATLAS thus represents a preserved fragment of an ancient planetary system.

Source: 


Link: https://www.nature.com/articles/s41586-026-10771-6

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, June 22 '26)

 


{Excerpt}

(...)

Time Period: June 07, 2026 - June 13, 2026

    -- A(H5) Detection4 site(s) (0.9%)

    -- No Detection442 site(s) (99.1%)

    -- No samples47 site(s)


{Click on Image to Enlarge}



(...)

Source: 


Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html?

____

#UK Health Security Agency# update on the #hantavirus cruise ship #outbreak (June 22 '26): All remaining quarantined passengers released from isolation

 


Latest update

    The UK Health Security Agency (UKHSA) can confirm that all remaining individuals have now left Arrowe Park.

    All passengers from the MV Hondius who subsequently returned to the UK have now completed their self-isolation periods.

    Professor Robin May, Chief Scientific Officer at UKHSA, said: 

    ''We would like to reiterate our thanks and gratitude to passengers, crew and other contacts for their cooperation throughout what has been a very challenging time for everyone affected.

    ''Our teams will continue to work closely with local authorities and the NHS to ensure everyone affected by this outbreak has the necessary support in place.

Source: 


Link: https://www.gov.uk/government/news/ukhsa-update-on-the-hantavirus-cruise-ship-outbreak

____

#Australia - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 


{Click on Image to Enlarge}

__

By Liam Quinn from Canada - Brown Skua landing near a penguin colony. Uploaded by Snowmanradio, CC BY-SA 2.0, https://commons.wikimedia.org/w/index.php?curid=15465669

___

    This is the first detection of H5N1 HPAI clade 2.3.4.4b in a wild bird, in a single migratory brown skua (Stercorarius antarcticus). 

    This is the first detection of H5 HPAI in a wild bird Australia

    The virus is related to H5N1 HPAI clade 2.3.4.4b viruses detected in southern Indian Ocean territories

    The bird was displaying clinical signs of leg paralysis, weakness and dehydration at Cape Le Grand national park near Esperance, Western Australia

    Brown skuas are vagrant species that occasionally visit Australia. 

    There is no poultry production in the region. 

    Enhanced general and targeted surveillance is underway to determine the extent of infection. 

    An epidemiological investigation has commenced. 

    A public information strategy is being implemented. 

    All coordinates provided are approximate.

Source: 


Link: https://wahis.woah.org/#/in-review/7649

____

#Honduras - High pathogenicity avian #influenza viruses (Inf. with) (#poultry) - Immediate notification

 


    As a result of the ongoing operation of the epidemiological surveillance system, which actively promotes the detection and reporting of events, the Official Veterinary Services of Honduras (of the National Agri-Food Health and Safety Services, SENASA) received a report of a sudden high mortality rate at a breeding farm

    Upon receiving the notification, health authorities responded immediately to conduct an epidemiological investigation, collect samples, and place the premises under quarantine. 

    Following subsequent laboratory confirmation of high pathogenicity avian influenza (HPAI), SENASA proceeded to implement the protocols established in the National Plan for the Prevention, Early Detection, Control, and Eradication of Avian Influenza. 

    The control health measures included the culling of all breeding birds

    Likewise, at the hatchery that received batches of fertile eggs from that farm, 89,900 chicks and 315,979 incubated eggs were disposed of, following strict biosecurity protocols to ensure proper disposal. 

    Currently, the cleaning and disinfection of the facilities are underway

    For its part, SENASA maintains active surveillance of backyard birds through community-based epidemiological surveys, of wild birds by promoting reporting, and of production farms by strengthening biosecurity and targeted sampling. 

    To this end, communication processes and mandatory reporting have been strengthened, working jointly with the country’s poultry industry, other government institutions, and cooperation agencies to enhance surveillance and early detection of the disease. 

    Furthermore, through a communication and awareness campaign, biosecurity measures are being promoted in both commercial establishments and backyards. SENASA has already formally notified its trading partners of the event, and updates will be provided in future reports.

Source: 


Link: https://wahis.woah.org/#/in-review/7652

____

#Spain reported a locally acquired Crimean-Congo Hemorrhagic Fever (#CCHF), according latest ECDC report (June 22 '26)

 


(...)

Epidemiological summary

    This is the first report of the weekly seasonal surveillance reports on Crimean-Congo haemorrhagic fever (CCHF) infections in 2026.

    Since the beginning of 2026 and as of 17 June 2026, one country in Europe has reported locally acquired cases of CCHF: 

        ° Spain (one case).

    The case in Salamanca (Spain) is not unexpected as Hyalomma spp. – the main vectors of CCHF virus – are widely distributed across the region. 

    In addition, CCHF virus is known to circulate in local animal populations, and human cases have previously been reported there. 

    The timing of this case aligns with the expected seasonal pattern of CCHF in Spain, and is probably linked to increased tick activity.

(...)

Source: 


Link: https://www.ecdc.europa.eu/en/crimean-congo-haemorrhagic-fever/surveillance-and-updates/seasonal

____

Sunday, June 21, 2026

Science and Charity, Pablo Picasso (1897)

 


{Click on Image to Enlarge}

__

Public Domain. 

Source: 


Link: https://www.wikiart.org/en/pablo-picasso/science-and-charity-1897

____

Saturday, June 20, 2026

Epidemiological and Virological Characteristics of #H9N2 Avian #Influenza Virus in #Jiangsu Province, #China, 2024

 


Abstract

H9N2 avian influenza viruses inherently carry cross-species transmission potential, making continuous surveillance critical for pandemic prevention. This study focused on monitoring the 2024 H9N2 epidemic in Jiangsu Province’s external environment, analyzing its molecular evolution and receptor binding properties, assessing cross-species transmission and pandemic risks, and investigating serological antibody levels across different human populations. Environmental samples were collected from live poultry markets, farms, slaughterhouses, and bird habitats across Jiangsu, screened via quantitative PCR (qPCR), with positive samples used for virus isolation and whole-genome sequencing. Receptor binding properties were tested by hemagglutination assay, and H9N2 antibody levels were measured in 370 occupationally exposed individuals and 240 non-exposed individuals using hemagglutination inhibition (HI) assays. Among the 5779 collected samples, 6.89% tested H9N2-positive, and 12 strains belonging to the Eurasian lineage Y280-like clade G57 genotype were successfully isolated. All strains carried the HA-Q226L mutation, with 11 showing preferential binding to human α-2,6 receptors and one strain possessing dual receptor binding capability. Internal genes harbored mammalian adaptation mutations, and M2 proteins contained mutations conferring complete resistance to amantadine-class antiviral drugs. Serological tests revealed antibody positive rates of 4.05% in exposed populations and 2.5% in non-exposed populations, with no statistically significant difference between groups. These findings confirm that Jiangsu’s circulating H9N2 viruses have acquired human receptor preference and mammalian adaptation, posing silent infection and pandemic risks. Enhanced surveillance and the development of candidate vaccine stockpiles are strongly recommended.

Source: 


Link: https://www.mdpi.com/1999-4915/18/6/687

____

History of Mass Transportation: The Class 87 Diesel Shunter of the Romanian Railways

 


{Click on Image to Enlarge}

__

By Catalin Ghita, tramclub.org, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=8459457

Source: 


Link: https://en.wikipedia.org/wiki/Rolling_stock_of_the_Romanian_Railways#/media/File:Locomotiva_CFR_clasa_87.jpg

____

#Coronavirus Disease Research #References (AMEDEO, June 20 '26)

 



    Br J Anaesth

  1. SAFAVYNIA SA, Shanker A, Wang J, Choi JM, et al
    Neurophysiological correlates of delayed recovery of consciousness in a critically ill patient with COVID-19 with repeated cardiac arrest.
    Br J Anaesth. 2026 Jun 17:S0007-0912(26)00360-0. doi: 10.1016/j.bja.2026.
    PubMed        


    Int J Infect Dis

  2. KARANFIL O, Gullu D, Birinci S, Bayram S, et al
    Crimean-Congo Hemorrhagic Fever in Turkiye, 2017-2024: Evolving Epidemiology and Implications for Surveillance.
    Int J Infect Dis. 2026 Jun 18:108898. doi: 10.1016/j.ijid.2026.108898.
    PubMed         Abstract available

  3. CHENG A, Meng L, Wang J, Liu L, et al
    Post-Pandemic Forecasting of Pediatric Acute Respiratory Infections with Deep Learning: A Multi-Pathogen, Multi-Time-Horizon Study.
    Int J Infect Dis. 2026 Jun 17:108889. doi: 10.1016/j.ijid.2026.108889.
    PubMed         Abstract available

  4. LAUNAY O, Ansellem O, Dashraath P, Loubet P, et al
    PREGNANT WOMEN COVID-19 IMMUNISATION IN 2026: EVIDENCE, UNCERTAINTY AND PRIORITIES.
    Int J Infect Dis. 2026 Jun 13:108886. doi: 10.1016/j.ijid.2026.108886.
    PubMed         Abstract available


    J Infect

  5. KONG M, Gao HX, Song XD, Yang GJ, et al
    Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.
    J Infect. 2026 Jun 18:106799. doi: 10.1016/j.jinf.2026.106799.
    PubMed         Abstract available

  6. DONG S, Li M, Huo D, Zhao H, et al
    Impact of EV-A71 vaccination and non-pharmaceutical interventions on hand, foot, and mouth disease: A 14-year interrupted time series analysis.
    J Infect. 2026;93:106795.
    PubMed         Abstract available


    J Med Virol

  7. DINC HO, Uysal HK, Can G, Budak B, et al
    Booster mRNA Vaccination Prevents Breakthrough Severe COVID-19 Infections.
    J Med Virol. 2026;98:e71026.
    PubMed         Abstract available

  8. GUPTA S, Chaudhary A, Bhatnagar S
    SARS-CoV-2 Evolution and Its Implications for RT-PCR Diagnostic Performance.
    J Med Virol. 2026;98:e71023.
    PubMed         Abstract available

  9. MENG L, Cheng A, Tang D, Huang X, et al
    Molecular Epidemiology, Viral Load and Clinical Severity of Human Adenovirus-Associated Respiratory Infections in Hospitalized Children in Shanghai, 2021-2023.
    J Med Virol. 2026;98:e71011.
    PubMed         Abstract available

  10. CHANG S, Shin J, Park S, Park H, et al
    Limited Cross-Neutralization of Emerging SARS-CoV-2 BA.3.2.2 After LP.8.1-Updated Vaccination.
    J Med Virol. 2026;98:e71025.
    PubMed         Abstract available


  11. Correction to "Preconception COVID-19 Vaccination Reprograms Fetal Metabolism to Accelerate Intrauterine Recovery and Suppress Persistent Metabolic Memory".
    J Med Virol. 2026;98:e71017.
    PubMed        

  12. MARWAHA A, Alam B, Akbari AR
    Reviewing the Use of Oral Melatonin in Critically Ill Covid 19 Patients.
    J Med Virol. 2026;98:e71021.
    PubMed        


    J Virol

  13. ZENG H, Shi Y, Zhong Q, Tang R, et al
    RIG-I-dependent sensing of PEDV shapes epithelial antiviral immunity in the intestinal mucosa.
    J Virol. 2026 Jun 16:e0048326. doi: 10.1128/jvi.00483.
    PubMed         Abstract available


    Lancet

  14. ABUBAKAR I, Tellez D, Aldridge RW, Altare C, et al
    The UCL-Lancet Commission on Migration and Health: review of the state of progress.
    Lancet. 2026;407:2554-2576.
    PubMed         Abstract available

  15. SASIENI P, Falcaro M
    Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
    Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
    PubMed         Abstract available


  16. Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial.
    Lancet. 2026 Jun 17:S0140-6736(26)00761-0. doi: 10.1016/S0140-6736(26)00761.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Jun. 20 '26)

 


    Ann Intern Med

  1. KOUTOURATSAS T, Dammad T, Mylonakis E
    In outpatients with COVID-19 during Omicron variant circulation, some antivirals reduce time to recovery.
    Ann Intern Med. 2026 Jun 2. doi: 10.7326/ANNALS-26-01878.
    PubMed         Abstract available

  2. COTTON D
    "Never More Than 15 Feet From the Respirator": Housestaff Research During the 1955 Boston Polio Epidemic.
    Ann Intern Med. 2026 Apr 28. doi: 10.7326/ANNALS-25-05440.
    PubMed         Abstract available


    Arch Virol

  3. AHMADY A, Mickleburgh I, Bryant N, Carnell GW, et al
    Enhanced virucidal activity of quaternary ammonium compound-thymol combinations: influence of mucin and mucoadhesive polymers.
    Arch Virol. 2026;171:215.
    PubMed         Abstract available

  4. SANYAL D, Chaubey B
    SARS-CoV-2 3CL protease interaction with host factors - identifying novel drug targets.
    Arch Virol. 2026;171:202.
    PubMed         Abstract available


    BMC Pediatr

  5. GRUENDL M, Campos LN, Dey T, Nkurunziza T, et al
    Epidemiology of children and adolescents undergoing surgery at Mexican public hospitals: a retrospective registry-based analysis from 2010 to 2022.
    BMC Pediatr. 2026;26:553.
    PubMed         Abstract available

  6. KARADENIZ HB, Zilan S, Yazici MB, Derelioglu SS, et al
    COVID-19 and first permanent molar extractions in children: a comparative retrospective study.
    BMC Pediatr. 2026;26:567.
    PubMed         Abstract available


    Cell

  7. UEKI H, Tomita Y, Duong C, Mitake H, et al
    A CRISPR knockout mouse library for functional genomics in influenza research.
    Cell. 2026 Jun 16:S0092-8674(26)00591-X. doi: 10.1016/j.cell.2026.
    PubMed         Abstract available


    Epidemiol Infect

  8. NEMCOVA B, Goldstein IH, Sebastian J, Minin VM, et al
    Unjustified Poisson assumptions lead to overconfident estimates of the effective reproductive number.
    Epidemiol Infect. 2026;154:e79.
    PubMed         Abstract available


    J Epidemiol Community Health

  9. MOSCROP A, Dorling D, Cole T
    'British children are not shrinking', but child height is increasing for the wrong reasons: trends and inequalities in child measurement programme data for England, Scotland and Wales.
    J Epidemiol Community Health. 2026;80:534-540.
    PubMed         Abstract available


    J Gen Virol

  10. NABIL NM, Tawakol MM, Hagag N, Eid S, et al
    Molecular surveillance and predictive risk modelling of avian influenza virus in wild birds in Egypt.
    J Gen Virol. 2026;107:002278.
    PubMed         Abstract available


    J Infect

  11. LU L, Long Z, Chen F, Li Z, et al
    Global Disability-Adjusted Life Years Burden of Lower Respiratory Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, and Klebsiella pneumoniae, 1990-2021: A Systematic Analysis of the Global Burden of Disease Study 2021.
    J Infect. 2026 May 25:106768. doi: 10.1016/j.jinf.2026.106768.
    PubMed         Abstract available


    J Infect Dis

  12. NURMI V, Hedman L, Vapalahti K, Hepojoki J, et al
    Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations.
    J Infect Dis. 2026;233:e1374-e1385.
    PubMed         Abstract available

  13. CASERTA MT, Mariani TJ, Walsh EE, Gill SR, et al
    Nasal Biomarkers of Acute Illness Severity and Predictors of Recurrent Wheeze in Infants Infected With Respiratory Syncytial Virus.
    J Infect Dis. 2026;233:1027-1035.
    PubMed         Abstract available

  14. LIN DY, Mischell MA, Zhang X, Mollan KR, et al
    Incidence and Severity of Postacute Sequelae of SARS-CoV-2 Infection in the Omicron Era: A Prospective Cohort Study.
    J Infect Dis. 2026;233:1063-1068.
    PubMed         Abstract available


    J Virol

  15. LV C, Wang S, Song M, Wu J, et al
    The nicotinamide phosphoribosyltransferase inhibitor FK866 restricts influenza A virus replication by perturbing viral polymerase activity.
    J Virol. 2026 Jun 15:e0059126. doi: 10.1128/jvi.00591.
    PubMed         Abstract available

  16. NGUYEN X-D, Le BT, Bleich J, Espada C, et al
    Environmental temperature and relative humidity shape post-emission aerosol fate and airborne influenza transmission.
    J Virol. 2026 Jun 15:e0063426. doi: 10.1128/jvi.00634.
    PubMed         Abstract available

  17. HUI X, Tian X, Xue C, Ding S, et al
    KCMF1-mediated influenza A virus PB1 ubiquitination at K653 regulates viral replication.
    J Virol. 2026 Jun 15:e0048126. doi: 10.1128/jvi.00481.
    PubMed         Abstract available


    Lancet

  18. ABUBAKAR I, Tellez D, Aldridge RW, Altare C, et al
    The UCL-Lancet Commission on Migration and Health: review of the state of progress.
    Lancet. 2026;407:2554-2576.
    PubMed         Abstract available


    PLoS Comput Biol

  19. MCKINLEY TJ, Williamson DB, Xiong X, Salter JM, et al
    On real-time calibrated prediction for complex model-based decision support in pandemics: Part 2.
    PLoS Comput Biol. 2026;22:e1014299.
    PubMed         Abstract available

  20. SHEFFIELD T, Bruneau RC, Won S, Sale KL, et al
    Combining machine learning and iterative experiments to keep pace with emerging viral variants of concern.
    PLoS Comput Biol. 2026;22:e1014394.
    PubMed         Abstract available


    PLoS One

  21. HIRABAYASHI K, Lorman V, Wuller S, Aragon LV, et al
    Evaluation of steroids for acute COVID in the prevention of long COVID in children: An EHR and pediatric cohort study from the RECOVER Initiative.
    PLoS One. 2026;21:e0350888.
    PubMed         Abstract available

  22. ALENAZI S, Mohanty J, Srinivasan M, Samontaray DP, et al
    "The impact of COVID-19 on employee productivity and the future of remote work".
    PLoS One. 2026;21:e0351968.
    PubMed         Abstract available

  23. HEUDORF U, Kowall B
    All?cause excess mortality in Germany peaked during the late?2022 influenza period, exceeding peaks during SARS?CoV?2 waves (2020-2023).
    PLoS One. 2026;21:e0335982.
    PubMed         Abstract available

  24. KIM SJ, Kim J
    Symptom profiles and health-related quality of life in Korean adults with post-acute sequelae of SARS-CoV-2 infection (PASC): A latent profile analysis.
    PLoS One. 2026;21:e0351506.
    PubMed         Abstract available

  25. HOLDSWORTH L, Jackson M, Piggin L, Kambulandu M, et al
    The experiences of doctors in Lesotho during the COVID-19 pandemic: A qualitative study.
    PLoS One. 2026;21:e0350935.
    PubMed         Abstract available

  26. HELMSDAL G, Kristiansen MF, Gaard EK, Eysturoy BJ, et al
    Persistent symptoms, cognitive impairment, and clinical predictors of long COVID one year after Omicron infection: A clinical case-control study from the Faroe Islands.
    PLoS One. 2026;21:e0351564.
    PubMed         Abstract available

  27. KEHL-FLOBERG K, Freisberg E, Pop-Vicas A, Gangnon R, et al
    Long COVID risk by pre-infection symptoms and functional status: A retrospective cohort study of data from the All of Us Research Program.
    PLoS One. 2026;21:e0330793.
    PubMed         Abstract available

  28. BHAN PC, Schroeder M, Turchet D, Wen J, et al
    The time sensitivity of aspirational interventions: Evidence from a role-modeling RCT.
    PLoS One. 2026;21:e0350832.
    PubMed         Abstract available

  29. WHITE DL, NonoDjotsa ABS, Ahmed ST, Boyle SH, et al
    Association between deployment and Gulf War Illness and adverse COVID outcomes in a nationwide cohort of 1990-1991 Gulf Era war veterans in the VA's Million Veteran Program.
    PLoS One. 2026;21:e0348594.
    PubMed         Abstract available

  30. REID-WESTOBY C, Duku E, Gaskin A, Janus M, et al
    Chronic absenteeism in Canadian kindergarten classes, pre- and post-COVID-19, and its association with concurrent developmental vulnerability.
    PLoS One. 2026;21:e0345192.
    PubMed         Abstract available

  31. YANG SD, Qi F, Colwill K, Gingras AC, et al
    SARS-CoV-2 infection in female sex workers from Nairobi, Kenya early in the COVID-19 pandemic: Seroincidence and behavioural associations.
    PLoS One. 2026;21:e0327692.
    PubMed         Abstract available

  32. GEBRETEKLE GB, Lan M, Xi M, Ximenes R, et al
    Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis.
    PLoS One. 2026;21:e0351183.
    PubMed         Abstract available

  33. NISSLEY-TSIOPINIS J, Fleming PF, Chan W, Langberg JM, et al
    Cluster-randomized trial of Homework, Organization, and Planning Skills program compared to treatment as usual/waitlist for youth ages 11-14: Study protocol for conceptual replication.
    PLoS One. 2026;21:e0343894.
    PubMed         Abstract available

  34. EL-ATFY ES, Gadallah AM, Alsahangiti AM, Balogun OS, et al
    Laplace Transform-Based Nonparametric Test of Exponentiality against DMRL class with preservation under the Homogeneous Poisson Shock Model and applications in survival analysis and reliability.
    PLoS One. 2026;21:e0349216.
    PubMed         Abstract available

  35. FATIMA Z, Surette MD, Marttala S, Leto D, et al
    Microbiome analysis of bronchoalveolar lavage (BAL) specimens from immunocompromised patients with pneumonia compared to those from healthy volunteers.
    PLoS One. 2026;21:e0351562.
    PubMed         Abstract available

  36. TRAIN A, Vemuri KK, Coderre-Ball A, Silva-Valencia J, et al
    Prescription patterns of inhaler medications from 2017 to 2023: A retrospective study using Ontario administrative healthcare data.
    PLoS One. 2026;21:e0348119.
    PubMed         Abstract available

  37. VASUDEV C, Mishra S, Rathi A, Fledderjohann J, et al
    Diverse coping strategies for food insecurity: A qualitative study of economically precarious households in India in the context of COVID-19.
    PLoS One. 2026;21:e0350020.
    PubMed         Abstract available

  38. KHAM-KJING N, Kawila R, Tariyo P, Puapun K, et al
    Etiology of severe acute respiratory infections among adults in northern Thailand using multiplex PCR: A post-COVID-19 surveillance study (2023-2024).
    PLoS One. 2026;21:e0350198.
    PubMed         Abstract available

  39. GODBOLE N, Choi S, Shim K, Liu Y, et al
    A study protocol for mixed-methods evaluation of the structure, design, and availability of medical student wellbeing programs.
    PLoS One. 2026;21:e0351759.
    PubMed         Abstract available

  40. ROHAN H, Bochner AF, Brown L, Ortiz EM, et al
    COVID-19 alert level systems-Lessons learnt for future public health emergencies: A qualitative study.
    PLoS One. 2026;21:e0351209.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  41. LEVITT M, Marten B, Oren G, Ioannidis JPA, et al
    Reclassification and weighting of multiple causes of death: US death certificates 2003-2023.
    Proc Natl Acad Sci U S A. 2026;123:e2604493123.
    PubMed         Abstract available


    Vaccine

  42. MALHOTRA G, Bilguche A, Eades O, Loftus MJ, et al
    Coverage and missed opportunities for routine vaccination in adult travellers: a single-centre observational study.
    Vaccine. 2026;86:128735.
    PubMed         Abstract available

  43. KATANA EB, Kiiza D, Odongpiny EAL, Simbwa BN, et al
    Willingness to receive Ebola vaccines among pregnant and lactating women in Kampala, Uganda: insights from a post-outbreak cross-sectional study.
    Vaccine. 2026;86:128737.
    PubMed         Abstract available

  44. GIANNINI F, Hogan AB, Blyth CC, Glass K, et al
    Modelling the impact of long-acting monoclonal antibody, maternal vaccine and hybrid programs of RSV immunisation in temperate Western Australia.
    Vaccine. 2026;86:128731.
    PubMed         Abstract available

  45. DVORKIN J, Pico M, Guinazu G, Crespi MS, et al
    Residual burden of severe RSV disease in infants during the first season of maternal RSVpreF immunization in Argentina: A hospital-based, multicentre, retrospective cohort study.
    Vaccine. 2026;87:128773.
    PubMed         Abstract available

  46. QI X, Smolders C
    From COVAX deliveries to vaccination uptake in LMICs: a monthly panel analysis.
    Vaccine. 2026;86:128763.
    PubMed         Abstract available

  47. EIDEN AL, Zheng Y, Wang D, Frew PM, et al
    Changes in attitudes and beliefs about childhood vaccination among parents in the United States: A repeat cross-sectional survey before and after the COVID-19 pandemic.
    Vaccine. 2026;87:128760.
    PubMed         Abstract available

  48. DELLA CIOPPA G, Sahai N, Dodeur V, Dutton JL, et al
    Safety, immunogenicity, and dose ranging of a bivalent respiratory syncytial virus and human metapneumovirus glycoprotein F-molecular clamp vaccine candidate in older adults: 1-month interim analysis of an ongoing randomised, observer-blind, placebo-
    Vaccine. 2026;87:128772.
    PubMed         Abstract available

  49. MOROS A, Deulofeu M, Ribo M, Bosch-Rue E, et al
    Multiple monovalent COVID-19 PHH-1V vaccine adaptations elicit homologous and cross-neutralizing antibody responses in mice.
    Vaccine. 2026;87:128781.
    PubMed         Abstract available

  50. SPILA-ALEGIANI S, Massari M, Cutillo M, Menniti-Ippolito F, et al
    Safety of influenza vaccine during the vaccination campaign 2021/2022 in Italy: a self-controlled case series study.
    Vaccine. 2026;88:128806.
    PubMed         Abstract available

  51. BUSH C, Desai S, Wang H, Hsu WC, et al
    Incidence of outcomes relevant to vaccine safety monitoring in the general population, after influenza vaccination, and after respiratory infections: a descriptive analysis of four US claims databases, 2022-2023.
    Vaccine. 2026;88:128821.
    PubMed         Abstract available

  52. CHRISTOU-ERGOS M, Sabahelzain MM, Bolsewicz KT, Kaufman J, et al
    Australian adults' views on influenza vaccination: Implications for communication and service quality from a qualitative study.
    Vaccine. 2026;88:128846.
    PubMed         Abstract available

  53. LE MH, Tran ND, Nguyen TTT, Phan TTN, et al
    Willingness to pay for influenza vaccination among the elderly in Vietnam: A triple-bounded dichotomous choice analysis of economic and behavioral determinants.
    Vaccine. 2026;88:128852.
    PubMed         Abstract available


    Virus Res

  54. VALENZUELA-FUENZALIDA JJ, Velarezco LM, Silva V, Delgado F, et al
    Occurrence of Myocarditis in Patients Immunized with Different Types of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.
    Virus Res. 2026 May 20:199748. doi: 10.1016/j.virusres.2026.199748.
    PubMed         Abstract available

  55. MANZOOR M, Banday MS, Para BA, Rani VI, et al
    Mental health strain due to COVID-19: Psychological distress and somatic symptoms among health care workers and the general population in Kashmir, India.
    Virus Res. 2026;369:199753.
    PubMed         Abstract available

  56. TRAMONTOZZI C, Riccio A, La Frazia S, Svicher V, et al
    Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against respiratory syncytial virus.
    Virus Res. 2026;369:199743.
    PubMed         Abstract available

My New Space

Most Popular Posts